Back to top
more

Takeda Pharmaceutical Co. (TAK)

(Delayed Data from NYSE)

$14.16 USD

14.16
6,279,139

+0.44 (3.21%)

Updated Aug 1, 2025 03:59 PM ET

Pre-Market: $14.21 +0.05 (0.35%) 8:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?

by Zacks Equity Research

KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.

Ekta Bagri headshot

Will Strong Asceniv Sales Drive ADMA Biologics Further?

by Ekta Bagri

ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.

Zacks Equity Research

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

by Zacks Equity Research

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Ekta Bagri headshot

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

by Ekta Bagri

ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.

Zacks Equity Research

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?

by Zacks Equity Research

ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.

Ekta Bagri headshot

ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?

by Ekta Bagri

ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.

Urmimala Biswas headshot

Top 4 GARP Stocks With Attractive PEG Ratios to Watch

by Urmimala Biswas

Here we present four high-growth GARP picks based on discounted PEG. These are PAK, FIVN, LTM and MFG.

Ekta Bagri headshot

ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?

by Ekta Bagri

ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.

Zacks Equity Research

Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

TAK or DSNKY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Ekta Bagri headshot

Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?

by Ekta Bagri

Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice

by Zacks Equity Research

Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Best Value Stocks to Buy for April 30th

by Zacks Equity Research

SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025.

Zacks Equity Research

Best Income Stocks to Buy for April 30th

by Zacks Equity Research

SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025.

Zacks Equity Research

New Strong Buy Stocks for April 30th

by Zacks Equity Research

DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025.

Zacks Equity Research

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

TAK vs. DSNKY: Which Stock Is the Better Value Option?

by Zacks Equity Research

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Ekta Bagri headshot

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

by Ekta Bagri

AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.

Zacks Equity Research

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

TAK or DSNKY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks Equity Research

Will ADMA Biologics Stock Continue Its Momentum in 2025?

by Zacks Equity Research

ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.

Zacks Equity Research

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.